Literature DB >> 10894303

Efavirenz decreases methadone blood concentrations.

C Marzolini, N Troillet, A Telenti, P Baumann, L A Decosterd, C B Eap.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10894303     DOI： 10.1097/00002030-200006160-00036

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  13 in total

Review 1.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance.

Authors:  Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

Review 3.  A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.

Authors:  R Douglas Bruce; David E Moody; Frederick L Altice; Marc N Gourevitch; Gerald H Friedland
Journal:  Expert Rev Clin Pharmacol       Date:  2013-05       Impact factor: 5.045

Review 4.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.

Authors:  Jacques Fellay; Catia Marzolini; Laurent Decosterd; Kerry Powell Golay; Pierre Baumann; Thierry Buclin; Amalio Telenti; Chin B Eap
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

6.  Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics.

Authors:  E D Kharasch; D Whittington; D Ensign; C Hoffer; P S Bedynek; S Campbell; K Stubbert; A Crafford; A London; T Kim
Journal:  Clin Pharmacol Ther       Date:  2012-03-07       Impact factor: 6.875

7.  Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.

Authors:  Julio S G Montaner; Malte Schutz; Robert Schwartz; Dushyantha T Jayaweera; Alfred F Burnside; Sharon Walmsley; Michael S Saag
Journal:  MedGenMed       Date:  2006-05-10

Review 8.  Interindividual variability of methadone response: impact of genetic polymorphism.

Authors:  Yongfang Li; Jean-Pierre Kantelip; Pauline Gerritsen-van Schieveen; Siamak Davani
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

9.  Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.

Authors:  Mohammad-Reza Shiran; Martin S Lennard; Mohammad-Zafar Iqbal; Oldwale Lagundoye; Nicholas Seivewright; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Br J Clin Pharmacol       Date:  2009-01       Impact factor: 4.335

10.  Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models.

Authors:  Sk Mastan; K Eswar Kumar
Journal:  Diabetol Metab Syndr       Date:  2009-10-09       Impact factor: 3.320
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.